ArticleEndocrine connections2025
Micro- and Macrovascular Complications in Early-Onset Type 2 Diabetes in Indians: Prevalence and Predictors in a Prospective Cross-Sectional Study.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-Fasting Glucose Measures and Their Clinical Significance in Diabetes Diagnosis and Cardiovascular and Cancer Risk Prediction: A Narrative Review.International journal of molecular sciences · 2026Review
- Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: and Aims: The prevalence of T2DM is rising among young people, placing them at greater risk for complications. We studied the prevalence and predictors of micro- and macrovascular complications in early-onset diabetes subjects (EOD, <40 years) and compared with late-onset T2DM (LOD, ≥40 years). Methods: A total of 800 subjects (400 EOD, 400 LOD), matched for gender and diabetes duration, were prospectively recruited and assessed for the prevalence of peripheral neuropathy, retinopathy, nephropathy, and ASCVD. Multivariate logistic regression analyzed predictors of diabetes complications. Results: The median age at diagnosis of diabetes was 35 years in EOD and 48 years in LOD. Hypertension was more common in LOD (73.8% vs. 58.8%, p<0.001). EOD patients had higher HbA1c (7.9% vs. 7.7%, p<0.05) and worse lipid profiles (non-HDL-C 129 vs.118 mg/dL, p<0.05; triglycerides 146 vs.130 mg/dL, p<0.001; HDL-C 36 vs. 38 mg/dL, p<0.01). The prevalence of retinopathy and nephropathy were similar between groups, while peripheral neuropathy and ASCVD were more prevalent in LOD. Increasing diabetes duration was associated with higher risk of all microvascular complications (p<0.01-0.001), while the age at onset of T2DM predicted peripheral neuropathy, nephropathy and ASCVD (p<0.05-0.001). Retinopathy (p<0.001) and female (p<0.05) gender increased peripheral neuropathy risk. Nephropathy (p<0.05) and smoking (p<0.01) were major ASCVD predictors. Conclusion: EOD patients had worse glycemic and lipid profiles, but similar frequency of retinopathy and nephropathy as LOD. The high prevalence of microvascular complications in EOD may reduce productivity, highlighting the importance of early screening, better glycemic control, and timely complication management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.